Logo-ipp
Submitted: 05 Dec 2018
Accepted: 10 Feb 2019
ePublished: 23 Feb 2019
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Immunopathol Persa. 2019;5(1): e01.
doi: 10.15171/ipp.2019.01
  Abstract View: 645
  PDF Download: 517

Original

Effect of high dose versus low dose of atorvastatin therapy on inflammation and coagulation factors in type 2 diabetic patients; a randomized clinical trial study

Mitra Niafar 1 ORCID logo, Amir Bahrami 1, Neda Lotfi Yagin 2,3, Farzad Najafipour 1, Naser Aghamohammadzadeh 1, Vahideh Sadra 1 * ORCID logo

1 Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 Nutrition Research Center, Department of Biochemistry and Diet Therapy, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
3 Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
*Correspondence to Vahideh Sadra, Email: Sadra.vahideh@gmail.com

Abstract

Introduction: Statins are one of the most widely used therapies in different groups of patients not only because of cholesterol-lowering properties but also due to their non-lipid related mechanisms. However, the effects of atorvastatin on inflammatory and coagulation markers in type 2 diabetic patients are not well examined.

Objectives: To evaluate, the effects of two different doses of atorvastatin on lipid profile, inflammatory coagulation markers, and liver enzymes in type 2 diabetic patients. Patients and Methods: In a randomized double-blinded controlled trial, 150 diabetic patients were randomly assigned to get atorvastatin 10 mg/d (n = 74) or 40 mg/d (n = 76) for 12 weeks. The concentration of biomarkers was determined both at the onset of the study as well as at the completing time of the intervention.

Results: Significant differences between the mean levels of lipid profiles, fibrinogen, interleukin-1 (IL-1) and IL-6 were observed between two groups after three months treatment with atorvastatin 10 and 40 mg/d (P<0.05). Furthermore, significant improvement in all blood values after atorvastatin 40 mg/d ingestion was observed (P<0.05) except for homocysteine and creatine phosphokinase (CPK) levels (P>0.05).

Conclusion: Atorvastatin therapy especially with higher dose was associated with inflammation and coagulation parameters improvement in diabetic individuals. 

Keywords: Hydroxymethylglutaryl CoA (HMG-CoA) reductase, Atorvastatin calcium, Inflammation, Diabetes mellitus, Inflammation, Coagulation factors
Citation: Niafar M, Bahrami A, Lotfi Yagin N, Najafipour F, Aghamohammadzadeh N, Sadra V. Effect of high dose versus low dose of atorvastatin therapy on inflammation and coagulation factors in type 2 diabetic patients; a randomized clinical trial study. Immunopathol Persa. 2019;5(1):e01. DOI: 10.15171/ipp.2019.01.
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 645

Your browser does not support the canvas element.


PDF Download: 517

Your browser does not support the canvas element.